Skip to main content

Solitary Pulmonary Nodule

Respiratory
0
Pipeline Programs
5
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Respiratory is a $39.4B mature market dominated by established inhalers and combination therapies with significant patent cliff risk.

$39.4B marketMature→ Stable30 products15 companies

Key Trends

  • Consolidation around GSK's triple-therapy franchises (Trelegy, Breo, Anoro)
  • Major patent expirations 2026-2031 creating $7.8B revenue cliff
  • High clinical trial activity (4,862 trials) suggesting pipeline innovation despite market maturity

Career Verdict

Respiratory offers stable commercial careers but limited growth upside; best for professionals seeking established markets with strong commercial infrastructure rather than innovation-driven advancement.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1ELIQUISGrowing
$18.3B
Bristol Myers Squibb·Launch15.0yr
#3TRELEGY ELLIPTADeclining
$4.5B
GSK·Peak4.9yr
#4CREONDeclining
$1.5B
AbbVie·Approaching LOE
#5BREO ELLIPTADeclining
$1.4B
GSK·Peak4.9yr

Drug Class Breakdown

FXa Inhibitors
$18.3B(46%)

dominant market driver

Unknown/Undisclosed Mechanism
$9.7B(25%)

fragmented portfolio

GLP-1 Receptor Agonists
$7.4B(19%)

rapidly expanding

Pancreatic Enzymes
$1.5B(4%)

legacy product

Corticosteroid/LABA Combinations
$796M(2%)

patent cliff approaching

Long-Acting Muscarinic Antagonists
$456M(1%)

mature maintenance therapy

Career Outlook

Stable

Respiratory is a stable, mature market suitable for commercial and medical affairs professionals seeking established career paths, but offers limited growth or innovation-focused opportunities. The impending patent cliff ($7.8B+ revenue at risk 2026-2031) will drive near-term restructuring and consolidation, potentially reducing headcount in 2027-2028. Professionals should expect strong compensation in Medical Affairs and field roles but limited advancement into strategic or R&D positions.

Breaking In

New graduates should prioritize commercial, field-based, or Medical Affairs roles over R&D; respiratory offers structured training and stable compensation but limited innovation exposure, so pair this experience with cross-therapeutic skill-building for long-term mobility.

For Experienced Professionals

Experienced professionals should evaluate whether to maximize earnings in this mature, stable market or transition to higher-growth areas (oncology, cell therapy); respiratory consolidation 2027-2030 will reduce senior-level opportunities, so consider strategic moves before patent cliff impacts headcount.

In-Demand Skills

Commercial execution and territory managementMedical Affairs/Key Opinion Leader engagementRegulatory affairs and lifecycle managementInhalation device expertise and product trainingManaged care and payer negotiations

Best For

Brand ManagerMedical Science LiaisonRegional Sales ManagerField Medical RepresentativePayer Relations ManagerRegulatory Specialist

Hiring Landscape

$84K-$314K

The respiratory sector shows modest hiring momentum (510 jobs across tracked positions) concentrated in commercial and engineering roles, with AstraZeneca and GSK leading. Medical Affairs positions command premium salaries ($314K avg) but represent only 3% of openings, reflecting the mature market's focus on sales execution over innovation. Hiring velocity is moderate and reflects market consolidation rather than expansion, suggesting limited career progression opportunities for early-to-mid career professionals.

510
Open Roles
5
Companies Hiring
5
Departments

Top Hiring Companies

43Stable
70Growing
45Stable
15Stable

By Department

Commercial(23%)
$122K
Engineering(11%)
$111K
Medical Affairs(3%)
$314K
IT(4%)
$84K
Manufacturing(3%)

Respiratory hiring favors commercial and field-based roles over R&D; Medical Affairs roles offer premium compensation but are scarce, making this area competitive for specialized talent.

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Alliance Pharmaceuticals
2 programs
Evaluate the Utility of the ProLung China Test in the Diagnosis of Lung CancerN/A1 trial
Installation or registration of smartphone applicationN/A1 trial
Active Trials
NCT02726633Unknown500Est. Dec 2017
NCT02693496Unknown10,000Est. Oct 2025
Boston Scientific
Boston ScientificCA - Valencia
2 programs
iNod SystemN/A1 trial
iNod™ SystemN/A1 trial
Active Trials
NCT02832284Completed23Est. Jun 2017
NCT05804435Withdrawn0Est. Feb 2027
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
A Multi-Center Trial of the ProLung Test™N/A
Providence Therapeutics
1 program
A Multi-Center Trial of the ProLung Test™N/A1 trial
Active Trials
NCT01566682Completed420Est. Mar 2019
Johnson & Johnson
Johnson & JohnsonNEW BRUNSWICK, NJ
1 program
TeaM OUT InterventionN/A1 trial
Active Trials
NCT04574518Active Not Recruiting223Est. May 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Boston ScientificiNod™ System
Johnson & JohnsonTeaM OUT Intervention
Boston ScientificiNod System
Alliance PharmaceuticalsInstallation or registration of smartphone application
Alliance PharmaceuticalsEvaluate the Utility of the ProLung China Test in the Diagnosis of Lung Cancer
Providence TherapeuticsA Multi-Center Trial of the ProLung Test™

Clinical Trials (6)

Total enrollment: 11,166 patients across 6 trials

iNod™ Ultrasound-Guided Needle Biopsy System Study

Start: Jan 2025Est. completion: Feb 20270
N/AWithdrawn
NCT04574518Johnson & JohnsonTeaM OUT Intervention

Teachable Moment to Opt-out of Tobacco: Interactive Voice Response Quit Line for Veteran Active Smokers With Lung Nodules

Start: Aug 2022Est. completion: May 2026223 patients
N/AActive Not Recruiting

iNod System Human Feasibility Assessment

Start: Jan 2017Est. completion: Jun 201723 patients
N/ACompleted
NCT02693496Alliance PharmaceuticalsInstallation or registration of smartphone application

Mobile Lung Nodule Observatory for Worldwide, Evidenced-based Research

Start: Oct 2015Est. completion: Oct 202510,000 patients
N/AUnknown
NCT02726633Alliance PharmaceuticalsEvaluate the Utility of the ProLung China Test in the Diagnosis of Lung Cancer

Evaluate the Utility of the ProLung China Test in the Diagnosis of Lung Cancer

Start: May 2015Est. completion: Dec 2017500 patients
N/AUnknown
NCT01566682Providence TherapeuticsA Multi-Center Trial of the ProLung Test™

A Multi-Center Trial of the ProLung Test™

Start: Oct 2012Est. completion: Mar 2019420 patients
N/ACompleted

Related Jobs in Respiratory

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.